Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology

CING•2026-07-30

Phase 3 ADHD results published

Cingulate disclosed open-access publication of Phase 3 results for ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology.

Results were already presented in the peer-reviewed paper, not flagged for a future medical meeting.

The trial showed meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents.

The safety profile was described as favorable, reinforcing plans to advance CTx-1301 toward potential regulatory filing and commercialization.

Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology

Phase 3 ADHD results published

Related News

First Solar publishes 2026 Corporate Responsibility Report highlighting domestic manufacturing footprint

L.B. Foster promotes Jason Bowlin to SVP-Rail as Greg Lippard plans retirement

Truxton Q2 FY26 net income rises 29% to $6.88 million; revenue climbs 16% to $16.84 million

Truxton preliminary Q2 net income rises on wealth management strength

International Paper second-quarter sales miss estimates amid soft packaging demand